Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.5%

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) were down 6.5% during trading on Wednesday . The company traded as low as $22.65 and last traded at $22.66. Approximately 39,372 shares changed hands during trading, a decline of 75% from the average daily volume of 157,780 shares. The stock had previously closed at $24.24.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DNTH. Jefferies Financial Group raised their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Lifesci Capital raised shares of Dianthus Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Raymond James lifted their target price on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research report on Thursday, April 18th. Finally, HC Wainwright started coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They issued a “buy” rating and a $40.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus price target of $42.83.

Dianthus Therapeutics Price Performance

The stock’s 50 day moving average is $23.68 and its two-hundred day moving average is $21.30.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The business had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. On average, equities analysts expect that Dianthus Therapeutics, Inc. will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds have recently made changes to their positions in DNTH. Tower Research Capital LLC TRC acquired a new position in Dianthus Therapeutics in the fourth quarter valued at about $25,000. Citigroup Inc. bought a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $53,000. Acadian Asset Management LLC bought a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $303,000. Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at $390,000. Finally, Laurion Capital Management LP bought a new position in Dianthus Therapeutics in the 3rd quarter valued at $497,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.